Tislelizumab

替雷利珠单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameTislelizumab
Drug Alias NameTilelizumabTirelizumabTerelizumabtirellizumabTirolizumab +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsEsophageal adenocarcinomaMetastatic breast cancerGastroesophageal Junction Neoplasms +[45] 
Global Approved IndicationsEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaHodgkin Disease
Approved Indications in ChinaHodgkin Disease
Original Approved Country/TerritoryMainland China
Original Approved Date2019/12/26
Country/TerritoryCzechiaBelgiumBulgaria +[48] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeOne Medicines Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeigene Guangzhou Biologics Manufacturing Co LtdNovartis AgGlenmark Pharmaceuticals Sa +[21] 
Inactive CompaniesBeigene Ireland LtdSubei People's Hospital of Jiangsu ProvinceFresenius Kabi Usa Llc +[5] 
Active IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[37] 
Inactive IndicationsMetastatic breast cancerAngioimmunoblastic T-cell LymphomaLiver Neoplasms +[8] 

Other Information

ATC CodeL01FF09
Related LinksWikipediaDrugBankKEGG